Introduction
============

Cervical cancer is the fourth most frequent malignancy in women and the seventh overall worldwide \[[@b1-crt-2019-124]\]. In Korea, it is one of the common gynecologic cancers, representing 9.8% of newly diagnosed malignancies in women \[[@b2-crt-2019-124]\]. Although radical hysterectomy has been demonstrated as a standard treatment for International Federation of Gynecology and Obstetrics (FIGO) stage IA-IIA uterine cervix cancer patients, recurrence risk after radical hysterectomy remains in the range of 15% to 30% \[[@b3-crt-2019-124],[@b4-crt-2019-124]\]. After recurrence, only few treatment options are available, and the prognosis is generally poor. Adjuvant radiation and concurrent chemoradiation have been advocated to reduce recurrence rates, with unavoidable adverse effects such as bowel and urinary complications \[[@b5-crt-2019-124]-[@b7-crt-2019-124]\]. Methods predicting recurrence and survival are, therefore, important for counseling patients and in planning adjuvant treatment.

Although the FIGO staging system is considered the most powerful prognostic parameter, other clinicopathological parameters have been shown to have additional significance in predicting patient prognosis \[[@b8-crt-2019-124]\]. Certain clinical variables including pelvic lymph node metastases, parametrial involvement, positive surgical margins, tumor size, deep stromal invasion, and lymphovascular space invasion (LVSI) are used for prediction of recurrence or survival. Information about these variables aids in determining the appropriate recommendation for adjuvant therapy \[[@b9-crt-2019-124],[@b10-crt-2019-124]\]. While some of the factors are considered to be somewhat controversial, others are widely accepted prognostic factors.

Traditionally, adjuvant therapy was given on the basis of risk factors. Combinations of factors have been shown to be more reliable than single factors \[[@b11-crt-2019-124]-[@b14-crt-2019-124]\]. However, there has been no prior consensus about the relative importance of different prognostic markers for outcomes including overall survival (OS) and disease-free survival (DFS) for lymphatic and hematogenous recurrences. Models developed for the prediction of recurrence or survival have performed well in the populations in which they were designed, but few models have been externally validated \[[@b15-crt-2019-124]-[@b18-crt-2019-124]\]. In addition, there are no published independent models separately predicting OS and DFS for lymphatic and hematogenous recurrences.

The current study aims to develop and validate a prognostic model of early-stage cervical cancer patients using a large study cohort to provide more individualized predictions in clinical practice.

Materials and Methods
=====================

1. Patients
-----------

After obtaining approval from the local institutional review board, the medical records of the patients with early-stage cervical cancer from January 2000 to December 2008 were retrospectively reviewed from nine Korean Gynecologic Oncology Group (KGOG)-affiliated institutions. Patients were included if they had pathologically confirmed cervical cancer, a clinical diagnosis of FIGO stage IB-IIA disease, and who had undergone radical hysterectomy (type II or III) with pelvic and/or para-aortic lymphadenectomy. Patients treated with neoadjuvant chemotherapy before surgery, those with previous radiation therapy, those with incidentally found cervical cancer after simple hysterectomy, and those with rare cell types were excluded. Patients with insufficient data were also excluded from analysis. From a database of 1,553 patients, 1,441 satisfied the eligibility criteria. Before analysis, patients were allocated based on treatment institution to one of two groups: a train cohort (n=788 from Samsung Medical Center) and a test cohort (n=653 from other institutions) ([Fig. 1](#f1-crt-2019-124){ref-type="fig"}).

2. Selection of prognostic variables for survival and recurrence
----------------------------------------------------------------

To identify variables predicting survival, the following factors were tested: age, body mass index (BMI), histology, FIGO stage, tumor size, parametrial invasion (PMI), LVSI, depth of invasion (DI), lymph node metastasis (LNM, pelvic and/or para-aortic), positive resection margin (RM), pretreatment serum squamous cell carcinoma (SCC) antigen (Ag), hemoglobin (Hb), platelet level, and surgical method (laparotomy vs. laparoscopy). Age, BMI, tumor size, serum SCC Ag, Hb, and platelet level were considered continuous variables. FIGO stage, histology, PMI, LVSI, DI, LMN status (pelvic and para-aortic), positive RM invasion, and surgical method (laparotomy vs. laparoscopy) were considered categorical variables. The associations between clinicopathologic parameters were examined using the chi-square test, Fisher exact test, and the Pearson correlation test, as appropriate. DFS and OS were estimated using the Kaplan-Meier method and log-rank test. DFS was defined as the time interval from surgery to the first evidence of any recurrence or last follow-up. DFS to lymphatic recurrence and/or hematogenous recurrence was defined as the time interval from surgery to the first evidence of lymphatic and/or hematogenous recurrence, respectively. OS was described as the time interval from diag-nosis to date of death or last follow-up.

3. Model development
--------------------

A Cox proportional hazards regression analysis was performed on each of the individual factors for DFS, OS, hematogenous recurrence, and lymphatic recurrence to estimate individual risk ratios. Cox proportional hazards regression using stepwise and best-model options (Akaike's information criterion) identified the best combinations as predictors and obtained adjusted risk ratios. Variables with a p-value \< 0.05 in the univariate analysis were entered as candidate variables into a stepwise regression model (conditional backward selection was used to avoid sparse-data biases) \[[@b19-crt-2019-124]\]. The selected model was applied to original data, and the final model was selected with exclusion of factors with p-value of \> 0.05. We then calculated a risk score (RS) for each patient, which is the sum of the estimated coefficients multiplied by the value of the factors on the training set. We used this formula to compute RS on the test set.

4. Model validation
-------------------

For validation of the survival prediction model, we plotted the negative log p-values of the log-rank test using all possible cutoffs of RS from each model in both train and test cohort. In addition, we also constructed time-dependent receiver operating characteristic (ROC) curves using the Nearest Neighbor Estimation method and area under the curve (AUC) in both cohorts \[[@b20-crt-2019-124]\]. Last, we compared the traditional risk classification (e.g., low risk, intermediate risk, and high risk) to our risk model. Traditional risk was as follows: any one of LNM, PMI, positive RM is considered high risk, two or more of the following risk as intermediate risk; LVSI positive, more than DI 1/2, and tumor size of 4 cm, and the others were classified low-risk group. For the comparison, we also categorized the patients into three groups according to RSs of proposed model. The cutoffs between three groups were arbitrarily chosen by the distribution of the score. Kaplan-Meier survival curve was plotted according to each group.

5. Statistical analysis
-----------------------

Statistical analysis was performed using SAS ver. 9.4 (SAS Institute, Cary, NC) and R 3.3.2 (Vienna, Austria; <http://www.R-project.org/>). A p-value of \< 0.05 was considered significant.

6. Ethical statement
--------------------

All medical records were collected according to the protocol and case report forms approved by each institutional review board, which waived the requirement for informed consent.

Results
=======

Patient characteristics are listed in [Table 1](#t1-crt-2019-124){ref-type="table"}. Total of 1,441 patients were included, and there were significant differences in the stage, LVSI, resection margin, surgical method, and tumor size between train cohort (n=788) and test cohort (n=653). After a median follow-up period of 63.7 months (range, 3.0 to 183.3 months), 134 patients experienced recurrences, and there were 72 deaths. The 5-year recurrence rates were 91.8% and 92.1% in the train and test cohorts, respectively (p=0.867) ([Fig. 2](#f2-crt-2019-124){ref-type="fig"}).

1. Model development for prediction of survival and recurrence
--------------------------------------------------------------

Cox proportional hazards regression using stepwise and best-model options yielded statistically significant predictors of para-aortic lymph node metastasis (pa-LNM), histology, LVSI, DI, pelvic lymph node metastasis (p-LNM), and pretreatment serum Hb level for DFS (RS=1.46×adenocarcinoma+1.12×LVSI+1.08×deep third DI+0.63×p-LNM+2.16× pa-LNM--0.17×Hb) ([Fig. 3A](#f3-crt-2019-124){ref-type="fig"}). Pa-LNM, histology, DI, LVSI, stage, and pretreatment serum Hb level were significant factors for OS (RS=0.78×stage+1.58×adenocarcinoma+1.14× LVSI+1.21×deep third DI+2.31×pa-LNM--0.19×Hb) ([Fig. 3B](#f3-crt-2019-124){ref-type="fig"}). Pa-LNM, p-LNM, DI, and age were significant predictors for lymphatic recurrence (RS=1.89×deep third DI+2.27×p-LNM+ 4.45×pa-LNM--0.71×age) ([Fig. 3C](#f3-crt-2019-124){ref-type="fig"}). Histology, DI, pa-LNM, LVSI, and PMI were significant predictors of hematogenous recurrence (RS=1.92×adenocarcinoma+1.11×LVSI+1.69×deep third DI+1.61×pa-LNM+0.77×PMI) ([Fig. 3D](#f3-crt-2019-124){ref-type="fig"}). Notably, stage was not significantly related to hematogenous recurrence, and histologic type was not correlated to lymphatic recurrence.

Additionally, for evaluation of prognostic factors in different histologic type, we performed separate analysis for SCC and adenocarcinoma patients of entire cohort. The relative prognostic significance of each factor was plotted in a heatmap, in which bright yellow indicates more significance (less p-value) ([Fig. 4](#f4-crt-2019-124){ref-type="fig"}). [Fig. 4A](#f4-crt-2019-124){ref-type="fig"} shows significance of factors in entire cohort, and [Fig. 4B](#f4-crt-2019-124){ref-type="fig"} shows factors by different histologic type (SCC and adenocarcinoma). In SCC, but not in adenocarcinoma, pa-LNM was a significant risk factor for both DFS and OS ([Fig. 4B](#f4-crt-2019-124){ref-type="fig"}). For DFS and hematogenous recurrence in adenocarcinoma, tumor size was a significant risk factor, different from SCC. Laparoscopy was shown in dark yellow (borderline significance) for DFS in SCC, but not in adenocarcinoma, in our data.

2. Model validation
-------------------

For internal and external validation, we plotted p-values of the log-rank test using all possible cutoffs of RSs from each model. The p-values demonstrate the accurate performance of the model ([Fig. 5](#f5-crt-2019-124){ref-type="fig"}). The validation plot (blue line) also showed good performance except for lymphatic recurrence. The prognostic model for lymphatic recurrence was not well validated in the external cohort.

The model is further validated by calculated probabilities of an event at 2 and 5 years for OS, DFS, hematogenous recurrence, and lymphatic recurrence using time-dependent ROC curves ([Fig. 6](#f6-crt-2019-124){ref-type="fig"}). AUCs of train cohort (red line) and test cohort (blue line) are shown. In train cohort, AUCs of OS at 2 and 5 years were 0.939 and 0.882. As in [Fig. 6](#f6-crt-2019-124){ref-type="fig"}, except for the model for lymphatic recurrence, the proposed models were well validated in this ROC curve (AUCs in test cohort at 2 and 5 years were 0.799/0.723 for DFS, 0.823/0.794 for hematogenous recurrences, and 0.844/0.806 for OS, respectively).

3. Comparison of prediction by traditional risks and the proposed model
-----------------------------------------------------------------------

Our results indicate significant differences for histology, LVSI, and DI, none of which were traditionally seen as high-risk factors, between low and high-risk groups of proposed model within each traditionalrisk assessment group ([Table 2](#t2-crt-2019-124){ref-type="table"}). There is, therefore, a discrepancy between traditional risk factors and significant factors of the proposed model.

To compare prediction by traditional risks and the proposed model, RSs of DFS and OS by proposed model are plotted (blue dots for low risk, red dots for moderate risk, green dots for high risk of proposed model) according to traditional risk factor groups (e.g., low-risk factor, intermediate-risk factor, and high-risk factor) ([Fig. 7A](#f7-crt-2019-124){ref-type="fig"}). Although there were correlations between groups by traditional risk factors and proposed model-classified risk groups, a number of patients with discordancy were observed. The Kaplan-Meier plot indicates that the proposed model-classified risk groups ([Fig. 7C](#f7-crt-2019-124){ref-type="fig"}) showed more distinctive survival differences between each risk group than traditional risk groups ([Fig. 7B](#f7-crt-2019-124){ref-type="fig"}).

Discussion
==========

Several previous studies have attempted to identify prognostic factors in cervical cancer. However, these previous studies were limited by small patient numbers and retrospectively collected data \[[@b11-crt-2019-124],[@b13-crt-2019-124],[@b21-crt-2019-124]-[@b24-crt-2019-124]\]. Previous studies that evaluated the 12 prognostic models for early-stage cervical carcinoma underestimated DFS in all 12 models, and only a few of those models were applicable to other populations \[[@b25-crt-2019-124]\]. In a validation study of two prognostic models in 221 patients, Van de Putte et al. \[[@b26-crt-2019-124]\] concluded that both the prognostic index by Delgado et al. \[[@b3-crt-2019-124]\] and the classification by Sedlis et al. \[[@b5-crt-2019-124]\] could be applied to their patient groups. Compared to previous studies, our study is robust because of our use of a comparatively large number of patients treated in multiple institutions. The treatment guideline was nearly unchanged during the study time period, which was beneficial to this work. Additionally, we performed external validation using a separate data set, which is essential for general applicability of a predictive model.

There have been efforts to improve patients' survival outcomes with the use of adjuvant radiation (with or without chemotherapy). However, only the significant change in decreasing recurrence was shown, but not in survival \[[@b5-crt-2019-124],[@b27-crt-2019-124]\]. Prognostic indicators from pathologic findings in cervical cancer include histologic cell type, tumor size, tumor grade, LVSI, depth of cervical stromal invasion, surgical margins, and lymph node metastases status \[[@b27-crt-2019-124],[@b28-crt-2019-124]\]. Identifying risk factors for patients with early-stage cervical cancer is an important step for determination of adequate adjuvant therapy after radical hysterectomy. The prognosis of patients is affected by a number of risk factors that interact with each other. This may be related to the diversity of predictive value from various prognostic variables.

In contrast to traditional prognostic systems, which allocate patients into discrete risk groups, a statistical predictive model can generate a numerical probability of a clinical outcome. Combining weighted clinicopathologic variables, the proposed model can give more individualized predictions. It is not surprising that a predictive model performs better than the traditional staging system because it is better able to account for heterogeneity in tumor and patient characteristics. Another potential benefit of the predictive statistical model is that it is readily modifiable by adding other prognostic factors. Here, we report a discrepancy between traditional risk factors and proposed model-classified risks. Factors not expected to be high risk based on traditional risk assessment---such as histology, LVSI, and DI---showed significant differences for OS, DFS, and hematogenous recurrence in groups traditionally characterized as both low and high risk. Also, in traditional high-risk group, LNM, size, and pretreatment serum Hb level showed significant differences for OS and DFS between groups by proposed model-classified risks.

A recent phase 3, multicenter, prospective randomized trial, the Laparoscopic Approach to Cervical Cancer (LACC) Trial, concluded that laparoscopic radical hysterectomy in patients with cervical cancer was associated with lower rates of DFS and OS than open radical hysterectomy \[[@b29-crt-2019-124]\]. Similarly in our data, laparoscopy was associated with DFS with borderline significance in SCC. However, laparoscopy was not significant factor in adenocarcinoma. In LACC trial, histologic subtype of SCC was most common (with 67.1%-67.3%) compared to adenocarcinoma (25.6%-27.3%), and result would be mostly affected by squamous cell carcinoma. We could expect different outcomes between histologic types, and further study of adenocarcinoma is needed.

Although we constructed an improved prognostic model, there are a number of potential limitations in the current study that must be acknowledged. First, we included patients who received adjuvant therapy in the study population. The vast majority of literature supported that adjuvant radiotherapy or concurrent chemoradiotherapy may reduce the risk of recurrence in patients with cervical cancer with adverse risk factors \[[@b5-crt-2019-124],[@b6-crt-2019-124]\]. Therefore, the adjuvant therapy might blunt the effect of prognostic variables. The patient cohorts in this study may not represent the whole population with early-stage cervical cancer. For example, our sampled cohort had 5-year OS of 95.5%, which is considerably different than reports in other studies, such as an OS of 62.8% \[[@b30-crt-2019-124]\]. Adjuvant treatments may, in part, explain the remarkably good survival rates in this study. To overcome the limit of the study population, validation of the model in a less favorable prognostic group is necessary before it can be adopted more broadly. Our model was created with retrospectively collected data. Therefore, our study may have biases with patient selection, deficit of random assignment, and incomplete data collection. Prospective data collection could identify more definite prognostic factors that could explain outcomes more precisely. The use of multi-institutional study data could be considered as a limitation because multiple surgeons and pathologists from different institutions may not rely on the same treatment and management for cervical cancer patients. Other differences from the multiple centers may also exist. However, the use of multi-institutional study data could also be regarded as an advantage of our study, as our conclusions could be more generally applicable. Also, large sample sizes are important for studies focused on a patient group with a low rate of the event being studied. Recently, FIGO staging system for cervical cancer was revised. Notable difference would be increased sub-stage in IB disease by tumor size, and incorporation of nodal status in staging. We inevitably used prior 2014 FIGO staging, because analysis was had been performed with retrospectively collected data. At this point, confusion may occur due to using prior FIGO staging, and this could also be limitation of our study.

In conclusion, we developed a robust model that can predict the OS and DFS in patients with early-stage cervical cancer after surgery. The model was internally and externally validated. This model may provide more individualized predictions in clinical practice for early-stage cervical cancer. A prospective validation study in a population with diverse characteristics may be needed to improve the predictive accuracy of the model in the future.
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![Stepwise Cox proportional hazards regression analysis for disease-free survival (A), overall survival (B), lymphatic recurrence (C), and hematogenous recurrence (D) for prognostic model. HR, hazard ratio; CI, confidence interval; LN, lymph node; AD, adenocarcinoma; LVSI, lymphovascular space invasion; DI, depth of invasion; PMI, parametrial invasion; BMI, body mass index; SCC Ag, SCC, squamous cell carcinoma antigen. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](crt-2019-124f3){#f3-crt-2019-124}

![(A) Histogram showing significance of risk factors for disease-free survival (DFS), hematogenous recurrence, lymphatic recurrence, and overall survival (OS). (B) Histogram showing significance of risk factors by histologic type. LN, lymph node; SCC, squamous cell carcinoma; DM, diabetes mellitus; LVSI, lymphovascular space invasion; BMI, body mass index; AD, adenocarcinoma.](crt-2019-124f4){#f4-crt-2019-124}

![Validation of the model predicting disease-free survival (DFS) (A), hematogenous recurrence (B), lymphatic recurrence (C), and overall survival (OS) (D).](crt-2019-124f5){#f5-crt-2019-124}

![Time-dependent receiver operating characteristic curves of the prediction model for disease-free survival (DFS), hematogenous recurrence, lymphatic recurrence, and overall survival (OS) (A, at 2 years; B, at 5 years). Red line indicates train cohort, and blue line indicates test cohort. AUC, area under the curve.](crt-2019-124f6){#f6-crt-2019-124}

![Comparison of traditional risk groups and proposed model-classified risk groups and their prognostic significance. (A) Box plot of risk score according to traditional risk assessment. (B) Kaplan-Meier survival according to traditional risk groups. (C) Kaplan-Meier curve according to proposed model-classified risk groups. OS, overall survival; DFS, disease-free survival.](crt-2019-124f7){#f7-crt-2019-124}

###### 

Demographic and pathologic data of the train and test cohorts

  Characteristic                                      All patients (n=1,441)   Train cohort (n=788)   Test cohort (n=653)   p-value
  --------------------------------------------------- ------------------------ ---------------------- --------------------- ----------
  **Age (yr)**                                        48 (40-58)               48 (40-57)             48 (41-58)            0.514
  **BMI**                                             23.4 (21.4-25.8)         23.4 (21.4-25.5)       23.5 (21.4-25.8)      0.269
  **FIGO stage**                                                                                                            
   IB1                                                1,085 (75.3)             628 (79.7)             457 (70.0)            \< 0.001
   IB2                                                167 (11.6)               63 (8.0)               104 (15.9)            
   IIA                                                189 (13.1)               97 (12.3)              92 (14.1)             
  **Histology**                                                                                                             
   SCC                                                1,089 (75.6)             587 (74.5)             502 (76.9)            0.324
   Adenocarcinoma                                     352 (24.4)               201 (25.5)             151 (23.1)            
  **Tumor size (cm)**                                 2.7 (1.5-4.0)            2.5 (1.5-4.0)          2.8 (1.9-3.8)         0.028
  **Lymphovascular space invasion**                                                                                         
   Negative                                           791 (54.9)               453 (61.7)             338 (54.6)            0.010
   Positive                                           562 (39.1)               281 (38.3)             281 (45.4)            
  **Invasion depth**                                                                                                        
   Inner 1/3                                          445 (30.8)               266 (33.8)             179 (29.2)            0.030
   Middle 1/3                                         380 (26.4)               193 (24.5)             187 (30.5)            
   Deep 1/3                                           577 (40.0)               329 (41.8)             248 (40.4)            
  **Lymph node metastasis**                                                                                                 
   Negative                                           1,177 (81.7)             637 (80.8)             540 (83.1)            0.544
   Pelvic LN positive                                 239 (16.6)               138 (17.5)             101 (15.5)            
   Para-aortic LN positive                            21 (1.5)                 12 (1.6)               9 (1.4)               
  **Parametrial involvement**                                                                                               
   Negative                                           1,323 (91.8)             716 (90.9)             607 (93.2)            0.099
   Positive                                           116 (8.2)                72 (9.1)               44 (6.8)              
  **Resection margin**                                                                                                      
   Negative                                           1,381 (95.8)             770 (97.7)             611 (93.6)            \< 0.001
   CIN positive                                       16 (1.1)                 0                      16 (2.5)              
   Cancer positive                                    44 (3.1)                 18 (2.3)               26 (4.0)              
  **Surgical method**                                                                                                       
   Laparotomy                                         1,267 (87.9)             710 (90.1)             557 (85.4)            0.008
   Laparoscopy                                        173 (12.1)               78 (9.9)               95 (14.6)             
  **Serum SCC level (ng/mL)**                         1.2 (0.7-2.5)            1.2 (0.7-2.4)          1.2 (0.7-2.5)         0.693
  **Pretreatment serum hemoglobin level (g/dL)**      12.7 (11.8-13.5)         12.7 (11.8-13.4)       12.8 (11.9-13.5)      0.067
  **Pretreatment serum platelet level (×10^3^/μL)**   252 (211.5-299.0)        250.0 (211.5-296.5)    255.5 (218.0-299.0)   0.140

Values are presented as median (range) or number (%). BMI, body mass index; FIGO, International Federation of Gynecoloy and Obstetrics; LN, lymph node; CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma.

###### 

Characteristics of proposed model-classified risk groups for OS and DFS within patients group by traditional risk assessment in cervical cancer

            Low risk by traditional risk   High risk by traditional risk                                                                
  --------- ------------------------------ ------------------------------- ------------ ----------- ---------- ----------- ------------ ----------
  **OS**    542                            9                                            60          102                                 
            Stage                                                                                                                       
                                           Ib1/IIa                         535 (98.7)   7 (77.8)    \< 0.001   59 (98.3)   50 (49.0)    \< 0.001
                                           Ib2                             7 (1.3)      2 (22.2)               5 (8.3)     52 (51.0)    
            Histology                                                                                                                   
                                           SCC                             511 (94.3)   1 (11.1)    \< 0.001   59 (98.3)   59 (57.8)    \< 0.001
                                           AD                              31 (5.7)     8 (88.9)               1 (1.7)     43 (42.2)    
            LVSI                                                                                                                        
                                           Negative                        469 (86.5)   5 (55.6)    0.030      32 (53.3)   4 (3.9)      \< 0.001
                                           Positive                        73 (13.5)    4 (44.4)               28 (46.7)   98 (96.1)    
            Invasion depth                                                                                                              
                                           Inner 1/3                       309 (57.0)   3 (33.3)    \< 0.001   17 (28.3)   0            \< 0.001
                                           Middle 1/3                      166 (30.6)   0                      26 (43.3)   3 (2.9)      
                                           Deep 1/3                        67 (12.4)    6 (66.7)               17 (28.3)   99 (97.1)    
            Lymph node metastasis                                                                                                       
                                           Negative                        542 (100)    7 (77.8)    NS         17 (28.3)   16 (15.7)    0.009
                                           Pelvic LN positive              0            0                      43 (71.7)   75 (73.5)    
                                           Para-aortic LN positive         0            2 (22.2)               0           11 (10.8)    
            Parametrial involvement                                                                                                     
                                           Negative                        542 (100)    9 (100)     NS         46 (76.7)   51 (50.0)    0.001
                                           Positive                        0            0                      14 (23.3)   51 (50.0)    
            Resection margin                                                                                                            
                                           Negative                        539 (99.4)   9 (100)     NS         52 (86.7)   87 (85.3)    0.741
                                           CIN positive                    3 (0.6)      0                      0           1 (1.0)      
                                           Cancer positive                 0            0                      8 (13.3)    14 (13.7)    
  **DFS**   566                            48                                                                                           
            Stage                                                                                                                       
                                           Ib1/IIa                         556 (98.2)   46 (95.8)   0.542      26 (78.8)   151 (74.0)   0.712
                                           Ib2                             10 (1.8)     2 (4.2)                7 (21.2)    53 (26.0)    
            Histology                                                                                                                   
                                           SCC                             517 (91.3)   2 (4.2)     \< 0.001   33 (100)    147 (72.1)   0.001
                                           AD                              49 (8.7)     46 (95.8)              0           57 (27.9)    
            LVSI                                                                                                                        
                                           Negative                        493 (87.1)   31 (64.6)   \< 0.001   27 (81.8)   11 (5.4)     \< 0.001
                                           Positive                        73 (12.9)    17 (35.4)              6 (18.2)    193 (94.6)   
            Invasion depth                                                                                                              
                                           Inner 1/3                       318 (56.2)   16 (33.3)   \< 0.001   8 (24.2)    2 (1.0)      \< 0.001
                                           Middle 1/3                      176 (31.1)   5 (10.4)               12 (36.4)   11 (5.4)     
                                           Deep 1/3                        72 (12.7)    27 (56.2)              13 (39.4)   191 (93.6)   
            Lymph node metastasis                                                                                                       
                                           Negative                        566 (100)    45 (93.8)   NS         23 (69.7)   23 (11.3)    \< 0.001
                                           Pelvic LN positive              0            0                      10 (30.3)   170 (83.3)   
                                           Para-aortic LN positive         0            3 (6.2)                0           11 (5.4)     
            Parametrial involvement                                                                                                     
                                           Negative                        566 (100)    48 (100)    NS         19 (57.6)   126 (61.8)   0.791
                                           Positive                        0            0                      14 (42.4)   78 (38.2)    
            Resection margin                                                                                                            
                                           Negative                        563 (99.5)   48 (100)    NS         23 (69.7)   180 (88.2)   0.018
                                           CIN positive                    3 (0.5)      0                      1 (3.0)     2 (1.0)      
                                           Cancer positive                 0            0                      9 (27.3)    22 (10.8)    

Values are presented as number (%). OS, overall survival; DFS, disease-free survival; SCC, squamous cell carcinoma; AD, adenocarcinoma; LVSI, lymphovascular space invasion; NS, not significant; LN, lymph node; CIN, cervical intraepithelial neoplasia.
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